Nasal flu vaccine may help reduce cases of group A strep, suggests UKHSA 


Share post:

The UK Health Security Agency (UKHSA) has suggested that the Live Attenuated Influenza Vaccine (LAIV) vaccine that offers protection to children against flu may also help reduce the rate of group A strep infections.

LAIV is a nasal spray offered each season to most children aged 2 and 3 years old, and to school-aged children, to help protect against flu.

The new study looked back at data from 2013 to 2017, comparing rates of group A strep (GAS) infections in pilot areas and comparing them to other areas where the vaccine was not being offered as widely.

It was found that incidence of GAS was lower in pilot areas where the LAIV vaccine was being offered to all primary school children, compared to areas where it was being incrementally rolled out.

The study revealed, in 2 to 4 year olds, rates of GAS were 73.5 per 100,000 children in pilot areas, compared to 93 per 100,000 children in non-pilot areas. In 5 to 10 year olds, rates of GAS were 50.3 per 100,000 children in pilot areas, compared to 57.8 per 100,000 in non-pilot areas.

Dr Jamie Lopez Bernal, Consultant Epidemiologist for Immunisation and Countermeasures at UKHSA, said: “Our findings suggest that the nasal spray vaccine programme, which offers very good protection against flu, may also help contribute to reductions in the rates of GAS infections among children.

“The nasal spray flu vaccine given to school-aged children and pre-schoolers has an excellent safety record and has been given to millions of children in the UK and worldwide.”

UKHSA has urged the parents and guardians of any reception and primary school aged children who missed their vaccination to contact their local school-aged vaccination service.

This winter the vaccine is also available for secondary school aged children from school years 7, 8 and 9 in December and January.


Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...

Grundon launches maiden UK-wide inhaler recycling programme

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and...

‘Record fine imposed on hydrocortisone manufacturers for dominant position abuse and 10,000% price increase’

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority’s (CMA) findings against two pharmaceutical manufacturers...

Vision Report: Legal reforms, adequate funding imperative for success of community pharmacy

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document...